Search

Your search keyword '"Pica, Roberta"' showing total 12 results
Start Over Author "Pica, Roberta" Publisher elsevier b.v.
12 results on '"Pica, Roberta"'

1. Enteropathic spondyloarthritis: Results from a large nationwide database analysis

Author

Zullo, Angelo, Caso, Francesco, Costa, Luisa, Tomietto, Paola, Fabio, Fischetti, Scolieri, Palma, Navarini, Luca, Cuccagna, Elisa, Severino Martin-Martin, Luis, Lia Scribano, Maria, Faggiani, Roberto, Pagnini, Cristiano, Mocci, Giammarco, Demurtas, Mauro, Tursi, Antonio, Festa, Stefano, Zerboni, Giulia, Pica, Roberta, Ridola, Lorenzo, Paroli, Marino, Baccini, Flavia, Baincone, Livia, Gabrielli, Armando, Afeltra, Antonella, Scarpa, Raffaele, Picchianti-Diamanti, Andrea, Lorenzetti, Roberto, Chimenti, Maria Sole, Luchetti, Michele Maria, Conigliaro, Paola, Canofari, Claudia, Benfaremo, Devis, Bruzzese, Vincenzo, Laganà, Bruno, and Perricone, Roberto

Published
2020
Full Text
View/download PDF

3. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.

Author

Pica, Roberta, Cassieri, Claudio, Cocco, Andrea, Zippi, Maddalena, Marcheggiano, Adriana, De Nitto, Daniela, Avallone, Eleonora Veronica, Crispino, Pietro, Occhigrossi, Giuseppe, and Paoluzi, Paolo

Abstract

Background Mesalazine is used as maintenance therapy in ulcerative colitis but the optimal dosage is still controversial. Aim To compare the remission-maintenance efficacy and tolerability of two daily doses of oral mesalazine (4.8 g and 2.4 g) in patients with ulcerative colitis with frequent relapses in a randomized controlled trial. Methods 112 ulcerative colitis patients in remission were enrolled and randomly allocated to treatment for 1 year with oral mesalazine at a daily dose of 4.8 g ( n = 56, Group A) or 2.4 g ( n = 56, Group B). Results At the end of the 12 months, intention to treat analysis revealed persistent remission in 42 (75%) in Group A and 36 (64.2%) in Group B ( p = 0.3). The higher daily dose (4.8 g) proved to be significantly more effective for maintaining remission in patients under 40 years of age (90.5% Group A vs. 50% Group B; Fisher's exact test, p = 0.0095) and in those with extensive disease (90.9% Group A vs. 46.7% Group B; Fisher's exact test, p = 0.0064). Conclusions In ulcerative colitis patients younger than 40 years and/or with extensive disease, a daily dose of 4.8 g oral mesalazine results in increased rates and duration of remission compared to 2.4 g. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

4. Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD).

Author

Daperno, Marco, Comberlato, Michele, Bossa, Fabrizio, Biancone, Livia, Bonanomi, Andrea G., Cassinotti, Andrea, Cosintino, Rocco, Lombardi, Giovanni, Mangiarotti, Roberto, Papa, Alfredo, Pica, Roberta, Rizzello, Fernando, D’Incà, Renata, and Orlando, Ambrogio

Abstract

Background Endoscopic activity has become a therapeutic endpoint in inflammatory bowel disease. Aim of this study was to evaluate inter-observer agreement for endoscopic scores in a real-life setting. Methods 14 gastroenterologists with experience in inflammatory bowel disease care and endoscopic scoring reviewed videos of ulcerative colitis ( n = 13) and postoperative ( n = 10) and luminal ( n = 8) Crohn's disease. The Mayo subscore for ulcerative colitis, Rutgeerts score for postoperative Crohn's disease, Crohn's disease endoscopic index of severity (CDEIS), and the simple endoscopic score-Crohn's disease (SES-CD) for luminal Crohn's disease were calculated. A subset of five endoscopic clips were assessed by 30 general gastroenterologists without specific experience in endoscopic scores. Kappa statistics and intraclass correlation coefficients were used to measure agreement. Results Mayo subscore agreement was suboptimal: kappas were 0.53 (95% confidence interval 0.47–0.56) and 0.71 (0.67–0.76) for the two groups. Rutgeerts score agreement was fair: kappas were 0.57 (0.51–0.65) and 0.67 (0.60–0.72). Agreements for CDEIS and SES-CD were good: intraclass correlation coefficients for the two groups were 0.83 (0.54–1.00) and 0.67 (0.36–0.97) for CDEIS and 0.93 (0.76–1.00) and 0.68 (0.35–0.97) for SES-CD, respectively. Conclusion The reproducibility of endoscopic scores in inflammatory bowel disease remains suboptimal, which could potentially have major effects on therapeutic choices. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

6. Tu1938 Endoscopic Training Leads to a Significant Increase in Agreement of Endoscopic Scoring for Inflammatory Bowel Disease (IBD): Final Results of the Igibdendo Educational Project.

Author

Daperno, Marco, Comberlato, Michele, Bossa, Fabrizio, Biancone, Livia, Bonanomi, Andrea G., Cosintino, Rocco, Lombardi, Giovanni, Mangiarotti, Roberto, Papa, Alfredo, Pica, Roberta, Rabagliati, Matteo, Grassano, Luca, Gasparini, Mauro, Pagana, Guido, D'Inca, Renata, Orlando, Ambrogio, and Rizzello, Fernando

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results